Is Hadlima in Shortage in 2026?

If you've been told your pharmacy can't fill your Hadlima prescription, you may be wondering: is there a Hadlima shortage? The short answer is that as of early 2026, Hadlima (Adalimumab-bwwd) is not listed on the FDA's official drug shortage database. However, that doesn't mean it's easy to find.

Many patients across the country are reporting difficulty getting Hadlima at their local pharmacies. The reasons are complex — a mix of supply chain logistics, insurance policies, and the still-maturing biosimilar market. In this article, we'll break down what's really going on with Hadlima availability and what you can do about it.

What Is Hadlima and Why Do People Need It?

Hadlima is a biosimilar to Humira (Adalimumab), a biologic medication that treats serious autoimmune conditions. These include rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriasis, psoriatic arthritis, ankylosing spondylitis, hidradenitis suppurativa, uveitis, and juvenile idiopathic arthritis.

For many patients, Hadlima is a critical medication — going without it can mean flare-ups, disease progression, and serious complications. That's why availability matters so much. For a full overview of this medication, see what is Hadlima.

Is Hadlima Still Hard to Find?

Yes, for many patients. Even though there's no formal FDA shortage, real-world availability is a different story. Here's what patients are experiencing:

• Retail pharmacies: Many chain pharmacies (CVS, Walgreens, Rite Aid) do not routinely stock Hadlima. They may carry Humira or a different preferred biosimilar instead.
• Specialty pharmacies: These are often the primary channel for Hadlima, but patients who don't know they need to use one can hit a dead end at their retail pharmacy.
• Regional variation: Availability varies significantly by location. Some areas have plenty of stock; others have almost none.

Why Is Hadlima Hard to Find?

Several factors contribute to Hadlima's availability challenges:

1. Biosimilar Market Growing Pains

Hadlima launched in the US in July 2023 — that's less than three years ago. The biosimilar market for Adalimumab is still evolving, with multiple products (Amjevita, Hyrimoz, Cyltezo, and others) competing for market share. Pharmacies and insurance plans are still sorting out which biosimilars to prefer, and this creates inconsistent stocking.

2. Insurance Formulary Preferences

Insurance companies negotiate deals with biosimilar manufacturers. Your plan might prefer Amjevita over Hadlima, or vice versa. If Hadlima isn't the preferred product on your formulary, your pharmacy may not bother stocking it — and you may face higher co-pays or need prior authorization.

3. Specialty Pharmacy Requirements

Most insurance plans require biologics like Hadlima to go through specialty pharmacies. If you didn't know this and went to your local pharmacy, you'd be told it's "not available" — even though it could be shipped to you within days through the proper channel.

4. Pharmacy Ordering Patterns

Pharmacies stock medications based on demand. Since Hadlima is newer and less well-known than Humira, many pharmacies simply haven't had enough prescriptions to justify keeping it on the shelf. It's a chicken-and-egg problem: patients can't get it because it's not stocked, and it's not stocked because not enough patients are asking for it.

For a detailed breakdown, see our article on why Hadlima is so hard to find.

How Much Does Hadlima Cost in 2026?

One of Hadlima's biggest selling points is its price. Here's how it compares:

• Hadlima WAC: approximately $1,038 per carton (one 40 mg dose)
• Humira WAC: approximately $6,922 per carton

That's roughly an 85% discount compared to Humira's list price. For patients with insurance, the actual out-of-pocket cost depends on your plan's co-pay or coinsurance structure. Organon offers a $0 co-pay savings card for eligible commercially insured patients.

For patients without insurance, the cash price at retail can range from $1,000 to $1,500 per injection. Patient assistance programs may be available for those who qualify. For more savings strategies, read our guide on how to save money on Hadlima.

New Options and Developments in 2026

The biosimilar landscape continues to evolve. Here's what's new:

• More biosimilar competition: With multiple Adalimumab biosimilars now on the market, insurance plans are increasingly negotiating lower prices. This puts downward pressure on costs for all biosimilars, including Hadlima.
• Interchangeable biosimilars: Cyltezo (Adalimumab-adbm) has interchangeable status, meaning pharmacists can substitute it for Humira at the pharmacy counter. This makes the biosimilar market more accessible overall.
• Growing pharmacy adoption: As biosimilars become more mainstream, more pharmacies are beginning to stock them regularly. This trend should make Hadlima easier to find over time.
• Insurance formulary shifts: Many insurance plans are actively moving patients from Humira to biosimilars to save costs. If your plan recently added Hadlima to its formulary, availability at preferred pharmacies should improve.

How to Find Hadlima in Stock

Here's what you can do right now:

1. Use Medfinder: Go to medfinder.com to search for pharmacies near you that have Hadlima available.
2. Call your insurance: Find out if you need to use a specialty pharmacy and which one is in-network.
3. Contact Organon: Their patient support team can help you locate Hadlima and navigate insurance hurdles. Visit hadlima.com.
4. Ask your doctor: Your doctor's office may have relationships with specialty pharmacies and can facilitate faster fulfillment.
5. Consider alternatives: If Hadlima remains unavailable, your doctor can prescribe another Adalimumab biosimilar. See our alternatives guide.

For a complete walkthrough, read how to find Hadlima in stock near you.

Final Thoughts

While Hadlima isn't in an official FDA-listed shortage, the practical reality is that many patients struggle to fill their prescriptions. The good news is that this is a solvable problem. With tools like Medfinder, specialty pharmacy access, and multiple biosimilar alternatives, you can get the treatment you need.

If you're a patient dealing with Hadlima availability issues, don't wait — start exploring your options today. And if you're a healthcare provider looking for resources, check out our provider-focused shortage update.